Sign In
Buy CALA
$0.0002
+0 (+0%)
At Close: Jun 03, 2026
Implied Volatility Surging for Calithera Biosciences (CALA) Stock Options
09:47am, Wednesday, 13'th Jan 2021
Investors need to pay close attention to Calithera Biosciences (CALA) stock based on the movements in the options market lately.
INCB001158 Biliary Tract Cancer Data to be Presented at 2021 Virtual ASCO Gastrointestinal Cancers Symposium
05:03pm, Monday, 11'th Jan 2021
SOUTH SAN FRANCISCO, Calif., Jan. 11, 2021 (GLOBE NEWSWIRE) -- Calithera Biosciences, Inc. (Nasdaq: CALA), a clinical-stage biotechnology company focused on discovering and developing novel small mole
Calithera (CALA) Plunges as CANTANA Study on Telaglenastat Fails
12:02pm, Tuesday, 05'th Jan 2021
Calithera (CALA) tanks as CANTATA study on its lead pipeline candidate, telaglenastat, did not achieve its primary goal for RCC.
Calithera to Present at the H.C. Wainwright Virtual BioConnect 2021 Conference
07:04am, Tuesday, 05'th Jan 2021
SOUTH SAN FRANCISCO, Calif., Jan. 05, 2021 (GLOBE NEWSWIRE) -- Calithera Biosciences, Inc. (Nasdaq: CALA), a clinical-stage biotechnology company focused on discovering and developing novel small mole
Why Calithera, BioNano Genomics And More Are Moving Today
12:21pm, Monday, 04'th Jan 2021
Calithera Biosciences (NASDAQ: CALA) shares are trading lower after the company announced that its CANTATA study of Telaglenastat in Renal Cell Carcinoma did not achieve its primary endpoint. The comp
Why Calithera Biosciences Stock Is Plunging Today
12:15pm, Monday, 04'th Jan 2021
The company reported negative results from a clinical trial.
Calithera Biosciences Reports CANTATA Study of Telaglenastat in Renal Cell Carcinoma Did Not Achieve Primary Endpoint
07:00am, Monday, 04'th Jan 2021
-- Company will continue to advance telaglenastat KEAPSAKE trial in non-small cell lung cancer, arginase inhibitor CB-280 trial in cystic fibrosis and emerging pipeline
Calithera Biosciences Announces New Employment Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
04:55pm, Thursday, 31'st Dec 2020
SOUTH SAN FRANCISCO, Calif., Dec. 31, 2020 (GLOBE NEWSWIRE) -- Calithera Biosciences, Inc. (Nasdaq: CALA), a clinical stage biotechnology company focused on discovering and developing novel small mole
Calithera Biosciences Announces New Employment Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
07:05am, Wednesday, 02'nd Dec 2020
SOUTH SAN FRANCISCO, Calif., Dec. 02, 2020 (GLOBE NEWSWIRE) -- Calithera Biosciences, Inc. (Nasdaq: CALA), a clinical stage biotechnology company focused on discovering and developing novel small mole
Calithera Biosciences Poised For Long-Term Success
12:44am, Wednesday, 25'th Nov 2020
Calithera has an important near-term catalyst that could launch the company into a significant commercialization opportunity by mid-year 2021. The company also is running a triplet therapy trial that
Calithera to Participate in Jefferies Virtual Healthcare Conference and SVB Leerink Oncology 1x1 Day
07:01am, Wednesday, 11'th Nov 2020
SOUTH SAN FRANCISCO, Calif., Nov. 11, 2020 (GLOBE NEWSWIRE) -- Calithera Biosciences, Inc. (Nasdaq: CALA), a clinical-stage biotechnology company focused on discovering and developing novel small mole
Calithera Biosciences Presents New Preclinical Data for CB-668 at Society for Immunotherapy of Cancer (SITC) 2020 Annual Meeting
07:00am, Monday, 09'th Nov 2020
IL4I1 inhibitor shows immune-mediated anti-tumor activity IL4I1 inhibitor shows immune-mediated anti-tumor activity
Calithera Biosciences' (CALA) CEO Susan Molineaux on Q3 2020 Results - Earnings Call Transcript
10:43am, Saturday, 07'th Nov 2020
Calithera Biosciences' (CALA) CEO Susan Molineaux on Q3 2020 Results - Earnings Call Transcript
Calithera Biosciences Reports Third Quarter 2020 Financial Results and Recent Highlights
04:06pm, Thursday, 05'th Nov 2020
--Calithera to Provide Corporate Update via Conference Call and Webcast at2:00 p.m. PT on November 5, 2020-- SOUTH SAN FRANCISCO, Calif., Nov. 05, 2020 (GLOBE NEWSWIRE) -- Calithera Biosciences, Inc.
Calithera Biosciences Announces Expansion of Ongoing Clinical Trial Evaluating Telaglenastat in Combination with palbociclib (IBRANCE®)
01:05pm, Wednesday, 04'th Nov 2020
Combination will be evaluated in patients with pancreatic ductal adenocarcinoma whose tumors have KRAS and CDKN2A mutations Combination will be evaluated in patients with pancreatic ductal adenocarcin
